Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer

NCT05942768 · clinicaltrials.gov ↗

COMPLETED

Status

103

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Adenocarcinoma

Interventions

DRUG: regorafenib plus anti-PD-1 antibodies

Sponsor

Hunan Cancer Hospital